I型干扰素在犬类疾病病原学及治疗方面的研究进展

doi:10.13560/j.cnki.biotech.bull.1985.2018-0851

生物技术通报 ›› 2019, Vol. 35 ›› Issue (11): 195-200.doi: 10.13560/j.cnki.biotech.bull.1985.2018-0851

I型干扰素在犬类疾病病原学及治疗方面的研究进展

胡文^{1, 3}, 冯珣¹, 张宝宝¹, 闫志伟¹, 徐玉生², 刘永生³

1. 甘肃警察职业学院,兰州 730046;
2. 公安部南昌警犬基地,南昌 330100;
3. 中国农业科学院兰州兽医研究所,兰州 730046

收稿日期:2018-09-30 出版日期:2019-11-26 发布日期:2019-11-19
作者简介:胡文,助理讲师,研究方向：警犬微生物学;E-mail：397969601@qq.com
基金资助:
甘肃警察职业学院科研项目（2018GJYXM02）

Research Advances on Type I Interferons Used for Understanding Etiology of Canine Diseases and Treatment of Them

HU Wen^{1, 3}, FENG Xun¹, ZHANG Bao-bao¹, YAN Zhi-wei¹, XU Yu-sheng², LIU Yong-sheng³

1. Gansu Police Vocational College,Lanzhou 730046;
2. Nanchang Police Dog Base of Ministry of Public Security of the People’s Republic of China,Nanchang 330100;;
3. Lanzhou Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Lanzhou 730046

Received:2018-09-30 Published:2019-11-26 Online:2019-11-19

摘要/Abstract

摘要： I型干扰素（Interferons,IFNs）是一类具有免疫学活性的细胞因子。这类细胞因子广泛参与到固有免疫和适应性免疫的激活和调节过程中,从而发挥抗病毒、抑制细胞增殖、调节免疫及抗肿瘤作用。目前I型IFNs主要用于临床治疗肾癌、黑色素瘤及慢性乙肝等疾病。一些I型IFN家族成员也已用于临床治疗犬细小病毒性肠炎、猫白血病病毒及猫免疫缺陷病病毒感染,但I型IFN的临床治疗还没有广泛用于各种犬类疾病的治疗当中。主要综述了犬类动物机体中I型IFN的免疫学活性以及其激活的下游免疫信号通路的最新研究进展,旨为犬类疾病研究人员提供一些有价值的参考信息。

关键词: 干扰素, 细胞因子, 犬类疾病, 临床治疗

Abstract: Type I interferons（IFNs）are a group of cytokines with immunological activity. Type I IFNs can function as antiviral role,inhibit cell proliferation,and regulate immunity and anti-tumor effect by the activation and regulation of adaptive and innate immune responses. To date,type I IFNs are mainly used for the therapy of human renal cancer,melanoma and chronic hepatitis B and so on. Some members of type I IFNs have been approved for the treatment of canine parvovirus,feline leukemia virus and feline immunodeficiency virus infections. However,type I IFNs have still not been used for the treatment of canine diseases. This paper reviews the latest advances on the immunologic competence of type I IFNs and IFNs-activated down-stream immune signal pathways,aiming to offer valuable references for researchers in canine diseases.

Key words: interferon, cytokine, canine diseases, treatment

胡文, 冯珣, 张宝宝, 闫志伟, 徐玉生, 刘永生. I型干扰素在犬类疾病病原学及治疗方面的研究进展[J]. 生物技术通报, 2019, 35(11): 195-200.

HU Wen, FENG Xun, ZHANG Bao-bao, YAN Zhi-wei, XU Yu-sheng, LIU Yong-sheng. Research Advances on Type I Interferons Used for Understanding Etiology of Canine Diseases and Treatment of Them[J]. Biotechnology Bulletin, 2019, 35(11): 195-200.

参考文献

[1] Outlioua A, Pourcelot M, Aroult D.The role of optineurin in antiviral type I interferon production[J]. Front Immunol, 2018, 9:853.
[2] Yang L, Xu I, Li Y, et al.Molecular and functional characterization of canine interferon-epsilon[J]. J Interferon Cytokine Res, 2013, 33:760-768.
[3] Bertolotto A.Evaluation of the impact of neutralizing antibodies on IFNbeta response[J]. Clin Chim Acta, 2015, 449:31-36.
[4] Spitzbarth I, Baumagartner W, Beineke A.The role of pro- and anti-inflammatory cytokines in the pathogenesis of spontaneous canine CNS diseases[J]. Vet Immunol Immunopathol, 2012, 147:6-24.
[5] Huang B, Qi ZT, Xu Z, et al.Global characterization of interferon regulatory factor(IRF)genes in vetebrates:glimpse of the diversification in evolution[J]. BMC Immunol, 2010, 11:22.
[6] Toledo Pinto TG, Batista-Silva LR, Medeiros RCA, et al.Type I interferons, sutophagy and host metabolism in Leprosy[J]. Front Immunol, 2018, 9:806.
[7] Yarbrough ML, Zhang K, Sakthivel R, et al.Primate-specific miR-576-3p sets host defense signaling threshold[J]. Nat Commun, 2014, 5:4963.
[8] Field AK, Tytell AA, Lampson GP, et al.Inducers of interferon and host resistance, V. In vitro studies[J]. Proc Natl Acad Sci USA, 1968, 61:340-346.
[9] Smith JS, Yager PA, Baer GM, et al.Minimal interferon induction in dogs, using a modified polyriboinosinic-polyribocytidylic acid complex[J]. Am J Vet Res, 1980, 41:1833-1835.
[10] Bridgman R, Rossi CR, Campos M.The sensitivity of domestic animal cell lines to eight recombinant human interferons[J]. J Interferon Res, 1988, 8:1-4.
[11] Hu CJ, Ozes ON, Klein SB, et al.Comparison of the in vitro host range of recombinant met-interferon-con 1, interferon-alpha 2b, and interferon-beta[J]. J Interferon Cytokine Res, 1995, 15:231-234.
[12] Zhang J, Yao Q, Liu Z.An effective synthesis method for tilorone dihydrocholoride with obvious IFN-alpha inducing activity[J]. Molecules, 2015, 20:21458-21463.
[13] Bienias M, Bruck N, Griep C, et al.Therapeutic approaches to type I interferonopathies[J]. Curr Rheumatol Rep, 2018, 20:32.
[14] Du CY, Zheng KY, Bi CW, et al.Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity[J]. Phytohter Res, 2015, 29:656-661.
[15] Krakowka S, Cummins JM, Ringler SS.The effects of human interferon-alpha upon in vitro canine immune responses[J]. Vet Immunol Immunopthol, 1988, 19:185-196.
[16] Berger Rentsch M, Zimmer G.A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon[J]. PLoS One, 2011, 6(10):e25858.
[17] Wang Y, Tian Q, Xu X, et al.Recombinant rabies virus expression IFNalpha 1 enhanced immune responses resulting in its attenuation and stronger immunogenicity[J]. Virology, 2014, 6:468-470.
[18] Yang F, Pan Y, Chen Y, et al.Expression and purification of canis interferon alpha in Escherichia coli using different tags[J]. Protein Expr Purif, 2015, 115:76-82.
[19] Yang L, Xu L, Li Y, et al.Molecular and functinal characterization of canine interferon-epsilon[J]. J Interferon Cytokine Res, 2013, 33:760-768.
[20] Kotredes KP, Gamero AM.Interferons as inducers of apoptosis in malignant cells[J]. J Interferon Cytokine Res, 2013, 33:162-170.
[21] Ivashkiv LB, Donlin LT.Regulation of type I interferon response[J]. Nat Rev Immunol, 2014, 14:36-49.
[22] Lee S, Hirohama M, Noguchi M, et al. Influenza A virus infection triggers pyroptosis and apoptosis of respiratory epithelial cells through type I IFN signaling pathway in a mutually exclusive manner[J]. J Virol, 2018, pii:JVI. 00396-18.
[23] Detje CN, Lienenklaus S, Chhatbar C, et al.Upon intranasal vesicular stomatitis virus infection, astrocytes in the olfactory bulb are important interferon beta producers that protect from lethal encephalitis[J]. J Virol, 2015, 89:2731-2738.
[24] Busnadiego I, Kane M, Rihn SJ, et al.Host and viral determinants of Mx2 antitiretroviral activity[J]. J Virol, 2014, 88:7738-7752.
[25] Haller O, Staeheli P, Schwemmle M, et al.Mx GTPases:dynamin-like antiviral machines of innate immunity[J]. Trends Microbiol, 2015, 23:154-163.
[26] Ulrich R, Puff C, Wewetzer K, et al.Transcriptional changes in canine distemper virus-induced demyelinating leukoencephalitis factor a biphasic mode of demyelination[J]. PLoS One, 2014, 9:e95917.
[27] Ito A, Isogai E, Yoshiok K, et al.Ability of orally administered IFN-alpha4 to inhibit naturally occuring gingival inflammation in dogs[J]. J Vet Med Sci, 2010, 72:1145-1151.
[28] Ban YH, Park SR, Yoon YJ.The biosynthetic pathway of FK506 and its engineering:from past achievements to future prospects[J]. J Ind Microbiol Biotechnol, 2016, 43:389-400.
[29] Pfankuche VM, Spitzbarth I, Lapp S, et al.Reduced angiogenic gene expression in morbillivirus-triggered oncolysis in a translational model for histiocytic sarcoma[J]. J Cell Mol Med, 2017, 21:816-830.
[30] Rossi UA, Gil-Gardeza ML, Villaverde MS, et al.Interferon-beta gene transfer induces a strong cytotoxic bystander effect on melanoma cells[J]. Biomed Pharmacother, 2015, 72:44-51.
[31] Su S, Huang S, Fu C, et al.Identification of the IFN-beta response in H3N2 canine influenza virus infection[J]. J Gen Virol, 2016, 97:18-26.
[32] Santoro D, Rodrigues Hoffmann A.Canine and human atopic dermatitis:two faces of the same host-microbe interaction[J]. J Invest Dermatol, 2016, 136:1087-1089.
[33] Saridomichelakis MN, Olivry T.An update on the treatment of canine atopic dermatitis[J]. Vet J, 2016, 207:29-37.

I型干扰素在犬类疾病病原学及治疗方面的研究进展

Research Advances on Type I Interferons Used for Understanding Etiology of Canine Diseases and Treatment of Them

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李丹, 杜梦潭, 修明霞, 刘兴健, 张志芳, 李轶女. 羊α干扰素在家蚕中的表达及抗小反刍兽疫病毒活性测定[J]. 生物技术通报, 2022, 38(1): 187-193.
[2]	杨威, 伍茜, 程建国, 罗燕, 王印, 杨泽晓, 姚学萍. 林麝干扰素α基因克隆、表达及转录调控分析[J]. 生物技术通报, 2022, 38(1): 194-204.
[3]	赵鸿远, 王朝, 成温玉, 马宁宁, 李曼, 魏小丽. 抗非洲猪瘟病毒制剂的研究进展[J]. 生物技术通报, 2021, 37(5): 174-181.
[4]	卢晓颖, 黄宝松, 马骞, 陈刚, 王忠良, 黄建盛, ERICAMENYOGBE, 谢瑞涛, 邓文鑫. 杂交石斑鱼干扰素调节因子3（IRF3）基因的克隆及表达分析[J]. 生物技术通报, 2019, 35(10): 144-151.
[5]	卫瑞阳, 白杰, 徐彬, 席燕燕, 王琳燚, 王改利, 付趁, 魏凤仙, 李绍钰. Lsa蛋白对金黄色葡萄球菌介导的炎性细胞因子表达的影响[J]. 生物技术通报, 2018, 34(1): 215-222.
[6]	黄演婷, 卢雪梅, 杨小蓉, 金小宝, 朱家勇. 重组融合蛋白Trx-IFN-CSP复性工艺研究[J]. 生物技术通报, 2016, 32(6): 219-225.
[7]	孙赛红, 马普, 孙鹤, 孔德荣, 李慧, 仇雪梅, 姜志强, 刘海映, 刘洋, 刘圣聪, 孟雪松, 王秀利，. 红鳍东方鲀（Takifugu rubripes）干扰素调节因子2基因的克隆及原核表达[J]. 生物技术通报, 2016, 32(5): 107-113.
[8]	刘兴健, 李皓洋, 胡小元, 张志芳, 易咏竹, 李轶女. 猪γ干扰素在家蚕中的表达和抗病毒活性检测[J]. 生物技术通报, 2016, 32(1): 144-148.
[9]	李皓洋, 胡小元, 易咏竹, 杨鑫, 张志芳, 李轶女. 犬α干扰素在家蚕杆状病毒表达系统中的表达及其抗病毒活性的测定[J]. 生物技术通报, 2015, 31(6): 216-220.
[10]	马普,孙赛红,王玉芳,李慧,刘海映,姜志强,仇雪梅,刘洋,张涛,王秀利. 红鳍东方鲀干扰素γ基因的原核表达[J]. 生物技术通报, 2015, 31(12): 174-179.
[11]	姜正军, 刘树海, 王茂超, 程全明, 黄金. 毕赤酵母高密度培养表达鸡α-干扰素的工艺研究[J]. 生物技术通报, 2014, 0(6): 115-119.
[12]	孙亭亭, 冀斌, 马志亮, 胡文丽, 鲁琼芬, 张雄伟, 陈培富. 红色原鸡外周血单个核细胞IFN-γ的诱导表达及其荧光定量PCR检测[J]. 生物技术通报, 2014, 0(4): 102-108.
[13]	林彬彬, 张彬, 李凤娜, 李颖慧, 范觉鑫. 免疫应激的作用机制及对动物生长的影响[J]. 生物技术通报, 2014, 0(3): 50-54.
[14]	李田田, 杨灵, 易咏竹, 沈桂芳, 张志芳, 李轶女. 鸡α干扰素在家蚕中的表达及抗病毒活性测定[J]. 生物技术通报, 2014, 0(3): 171-176.
[15]	张明杰. 人LL-37与干扰素α2a密码子的优化及其在毕赤酵母中的融合表达[J]. 生物技术通报, 2014, 0(11): 206-213.